@wbbsec

WBB Securities is a leading investment management, investment banking, and equity research firm focused primarily in the life science niche.

 Cranford, NJ
wbbsec.com
Joined March 2014
  • Tweets917
  • Following300
  • Followers410
62Media
Medical innovation cannot be measured by scientific achievement alone. As new therapies transform what is possible, the challenge is ensuring that innovation, affordability, and patient access can advance together. Read the full article: forbes.com/sites/stephenbroz…

What Price Healthcare? RevMed’s Rasonque And The U.S. Drug Pricing Paradox

RevMed’s Rasonque may show our greatest medical advances may become products that society celebrates but increasing numbers of patients cannot obtain.

forbes.com
42
New in @Forbes from Dr Steve Brozak: What Price Healthcare? RevMed’s Rasonque-The US Drug Pricing Paradox via @forbes forbes.com/sites/stephenbroz… What should healthcare value: the price of a treatment or the long-term value it delivers to patients? #Biotech #Healthcare #DrugPricing

What Price Healthcare? RevMed’s Rasonque And The U.S. Drug Pricing Paradox

RevMed’s Rasonque may show our greatest medical advances may become products that society celebrates but increasing numbers of patients cannot obtain.

forbes.com
1
2
77
Is biotechnology investing or speculation? Dr Brozak's latest @Forbes article explores what Warren Buffett's warning about today's "gambling mood" in the markets means for biotech investors and why disciplined analysis still matters. forbes.com/sites/stephenbroz…

Is Warren Buffett’s Stock Gambling Warning Bad For Biotechnology?

Buffett’s casino comments raise an uncomfortable truth. Is biotechnology an investment, or is it more of a gambling casino? The honest answer is that it can be either.

forbes.com
1
96
🚨 Tomorrow at 11:00 AM ET. How can we advance biotechnology while protecting against future biological risks? Join Steven Quay, MD, PhD, and Nicholas Wade for: "New Guardrails Required for Today's Pathogen Biology" Register: conference.demy-colton.com/b… #Biotech #Healthcare

New Guardrails Required for Today’s Pathogen Biology

New Guardrails Required for Today’s Pathogen Biology: We can do this & protect research

conference.demy-colton.com
36
How do we make pathogen research safer without slowing development? Former @nytimes science editor Nicholas Wade talks with Steven Quay, MD PhD, on the guardrails today's biology needs. Free virtual salon, Wed June 17 @ 11AM EST, live Q&A. Register conference.demy-colton.com/b…

New Guardrails Required for Today’s Pathogen Biology

New Guardrails Required for Today’s Pathogen Biology: We can do this & protect research

conference.demy-colton.com
1
35
In @forbeshealth, Dr. Steve Brozak reviews Steven Quay's The Code As Witness, laying out 5 "smoking gun" traits behind the case for Covid-19's lab origins and why institutional secrecy leaves us unprepared for the next pandemic. Read here: forbes.com/sites/stephenbroz…

‘The Code As Witness’ Is A Book About Science, Politics And Pandemic Inquiry

The Code as Witness written by Steven C. Quay is part scientific investigation, part policy strategy, and part warning about the future of biological research.

forbes.com
3
1
8
233
Why is the 2026 Ebola outbreak raising new concerns? Dr. Steve Brozak examines institutional distrust, attacks on healthcare infrastructure, delayed containment efforts, and global preparedness. Read here via @forbes forbes.com/sites/stephenbroz… #Ebola #GlobalHealth

Deaths, Burned Clinics — What’s Different About Ebola’s 2026 Return?

12-Yrs ago my Ebola piece was not about it arriving in the US. It was about an era where infectious disease could become a geopolitical & economic force. The era is now.

forbes.com
1
125
A WHO emergency meeting. Multiple countries monitoring cases. Questions about transmission, preparedness, and containment. In @forbeshealth, Dr. Steve Brozak examines 5 urgent questions emerging from the recent Hantavirus outbreak. Read here: forbes.com/sites/stephenbroz… #Hantavirus

5 Urgent Questions After The WHO Emergency Hantavirus Meeting

A 3-hour WHO Hantavirus emergency Zoom call was held this morning, providing outbreak analysis. It seemed that for every question asked many more questions were raised.

forbes.com
102
Steve Brozak examines HHS Secretary Robert F. Kennedy Jr.’s focus on the mental health crisis and psychiatric overprescribing and what can be done moving forward. "Our Mental Health Crisis: RFK Jr. Faces Psychiatric Over-Prescribing" via @forbes forbes.com/sites/stephenbroz…

RFK Jr. Examines Role Of Medication In Mental Health Care

The US mental health system has faced a conflict that policymakers and healthcare executives have been unwilling to confront, but HHS's RFK Jr. has just changed that.

forbes.com
64
WBB Sec President Dr Steve Brozak is moderating today’s #BiotechShowcase panel: “Working with ARPA-H: Federal Investment in Biotech & Healthcare Innovation.” Featuring ARPA-H leaders: Dr Jessica Green, Natalie Kates & Dr Paul Sheehan. 🔗 informaconnect.com/biotech-s… #BiotechShowcase

Agenda - Pre-Event Activities (Jan 10) | Biotech Showcase

Pre-Event Activities (Jan 10). Agenda for day 1 of Biotech Showcase

informaconnect.com
70
The US healthcare system faces a real stress test in 2026. In @Forbes, Dr Brozak examines how the potential ACA subsidy cliff exposes deeper structural risks in healthcare’s business model, from incentives to access to rising costs. Read more via @forbes forbes.com/sites/stephenbroz…

The U.S. 2026 Healthcare Cliff: When The Business Model Is The Real Risk

The likely expiration of enhanced Affordable Care Act (ACA)/Obamacare insurance subsidies are not simply an isolated policy event. Instead, they are a stress test.

forbes.com
5
8
1,526
OYE Therapeutics raises $5.475M Series A to advance high-concentration caffeine therapy for anesthesia recovery & OIRD. WBB Securities acted as placement agent. Phase 1 planned for Q1 2026. Congrats to the OYE team on reaching this important milestone. 🔗oyetherapeutics.reportablene…

OYE Therapeutics

OYE Therapeutics Raises $5.475 Million in a Series A to Advance Clinical Development of High-Concentration Caffeine Therapy for its anesthesia recovery and Drug Overdose Reversal

oyetherapeutics.reportablenews.com
29
Dr. Brozak describes why it’s critical to understand the role that Medicaid and Medicaid State-directed payments (SDPs) play in the survival of what are known as Safety Net Hospitals and the entire US Healthcare System. Via @Forbes forbes.com/sites/stephenbroz…

Diagnosing Medicaid Cuts To Hospitals In The One, Big, Beautiful Bill

It’s critical to understand the role that Medicaid and Medicaid State-directed payments (SDPs) play in the survival of what are known as Safety Net Hospitals.

forbes.com
1
48
WBB Securities acted as sole placement agent in #FELIQSCorp’s $9M Series A to advance FLQ-101, a novel treatment to prevent blindness in premature infants. #Biotech #ROP 🔗 feliqs.reportablenews.com/pr…

Feliqs

FELIQS Announces $9 Million Series A Financing to Advance FLQ-101 Clinical Program for Retinopathy of Prematurity

feliqs.reportablenews.com
1
42
WBB Securities retweeted
Sara Jane Demy@demy_sara26 May 2025
🎉 💬 We’re hosting our 50th complimentary #VirtualSalon w/a timely discussion on CD19 CAR-T therapies & their impact since @US_FDA approval. I would love for you to join us on May 28, from 11:00 AM – 12:00 PM ET. 👉 Complimentary registration: bit.ly/3Ed22d5
1
2
76
Seven years after the FDA's first approval, what have we learned about #CellTherapy and #GeneTherapy? Join the conversation at the @DemyColton Virtual Salon 🔗 conference.demy-colton.com/s… #Biotech #FDA #Innovation #LifeSciences #WBB
34
President Donald Trump – Will He Become The Drug Price Equalizer? via @forbes by Dr. Steve Brozak, WBB Sec. – Why US drugs are the world’s costliest and how Most Favored Nation will affect the pharma industry. forbes.com/sites/stephenbroz…

Can The Trump Administration’s Drug Price Equalization Really Happen?

Unlike Trump's first term, his proposed "most favored nation" policy, tying U.S. drug prices to the lowest prices paid by other developed countries, might make it this time.

forbes.com
25
Tariffs on pharmaceuticals could reshape the industry. In his latest @Forbes article, Dr. Steve Brozak examines how the U.S. dodged a bullet—for now. But can domestic manufacturing step up? Read more: forbes.com/sites/stephenbroz… #Pharma #Biotech #Healthcare #DrugShortages #Forbes

New Tariffs Could Send Drug Prices Soaring And Lead To Dire Shortages

As long as pharmaceutical tariffs are being considered, their potential threat to the pharmaceutical industry and the people it serves remains.

forbes.com
1
37
What will new tariffs mean for drug prices & availability? In his latest @Forbes piece, WBB Securities’ President Dr. Steve Brozak explores what’s ahead for pharma & the supply chain. Read more: @forbes forbes.com/sites/stephenbroz… #DrugPricing #Tariffs #Pharma #Healthcare

As Tariffs Begin, What Will They Do To Drug Prices And Availability?

The American public lacks transparency regarding the origin of their medications, and the assumption that their drugs come from domestic producers is largely inaccurate.

forbes.com
1
59
A Biotech Showcase panel convened to discuss the threat of H5N1 after the announcement of the first confirmed human case of bird flu. Only through innovative strategies will the threats of infections by H5N1 and other pathogens be effectively addressed forbes.com/sites/stephenbroz…

As H5N1 Is Detected In San Francisco, A Panel Discusses Next Steps

San Francisco confirmed that a child in the city became the first case of H5N1. A panel of biotech leaders discussed what options could be taken next.

forbes.com
3
6
4
9
8,050
Load more